Status:
COMPLETED
A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Lead Sponsor:
Seldar Pharma, Inc.
Conditions:
Diarrhea Predominant Irritable Bowel Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week tr...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent
- Men or women aged 18-75 years
- Patient has IBS with diarrhea (IBS-D)
- Ability to communicate with the investigator
Exclusion
- IBS with constipation (IBS-C) or mixed IBS (IBS-M)
- Other significant disease or condition that may interfere with trial completion
- Untreated lactose intolerance
- History of alcohol or drug abuse in past two years
- Participation in other clinical trials within prior month
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01896583
Start Date
November 1 2013
End Date
July 1 2014
Last Update
June 6 2019
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Elite Clinical Studies
Phoenix, Arizona, United States, 85018
2
Shahram Jacobs, M.D., Inc.
Encino, California, United States, 91436
3
Grossmont Center for Clinical Research
La Mesa, California, United States, 91942
4
Probe Clinical Research Group
Santa Ana, California, United States, 92701